Q3 2024 EPS Estimates for ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Lowered by Analyst

ThermoGenesis Holdings, Inc. (NASDAQ:THMO) – Research analysts at HC Wainwright dropped their Q3 2024 EPS estimates for shares of ThermoGenesis in a report issued on Tuesday, November 14th. HC Wainwright analyst S. Lee now expects that the company will post earnings per share of $0.02 for the quarter, down from their prior estimate of $0.03. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for ThermoGenesis’ current full-year earnings is ($3.26) per share. HC Wainwright also issued estimates for ThermoGenesis’ FY2024 earnings at $0.08 EPS.

ThermoGenesis Stock Down 17.9 %

Shares of THMO stock opened at $0.99 on Wednesday. ThermoGenesis has a 1 year low of $0.90 and a 1 year high of $6.75. The stock has a fifty day moving average price of $1.14 and a 200 day moving average price of $1.31.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in THMO. Raymond James & Associates purchased a new position in ThermoGenesis during the 1st quarter valued at about $66,000. Virtu Financial LLC purchased a new stake in shares of ThermoGenesis in the first quarter valued at about $35,000. Armistice Capital LLC acquired a new stake in shares of ThermoGenesis in the first quarter valued at approximately $328,000. Renaissance Technologies LLC purchased a new position in shares of ThermoGenesis during the 1st quarter worth approximately $42,000. Finally, Two Sigma Investments LP acquired a new position in shares of ThermoGenesis during the 1st quarter worth approximately $40,000. Institutional investors and hedge funds own 4.71% of the company’s stock.

About ThermoGenesis

ThermoGenesis Holdings, Inc develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market.